Facebook
LinKed
Twitter
Google

What other biotech news have you been missing? A big China IPO and more

29 DEC 2018
by john carroll — on December 24, 2018 10:14 AM EST
Updated: December 26, 2018 09:52 AM

https://endpts.com/what-other-biotech-news-have-you-been-missing-a-big-china-ipo-and-more/


After the Hong Kong ex­change saw the first slate of biotech IPOs plunge well below their debut price, the in­vest­ment crowd got more than a lit­tle wor­ried about what the fu­ture held for other Chi­nese play­ers look­ing to raise cash. But Shang­hai Jun­shi Bio­sciences has helped ease the fret­ting — for now — after watch­ing its stock leap on their roll­out Mon­day.

Ac­cord­ing to Reuters the com­pany raised close to $400 mil­lion and then cheered on a 22% surge in their stock price. And that fol­lows a suc­cess­ful launch for In­novent, an­other pre­mier China biotech, which has also seen a surge since their IPO some weeks ago.

As­cle­tis, the first to take the plunge, has seen 60% of its mar­ket cap dis­ap­pear after the his­toric first step this year. And BeiGene has also ex­pe­ri­enced heavy tur­bu­lence.

You need a license to cut-and-paste this copyrighted news content.
Use this link to purchase your paid subscription ($200/year for individuals and $1,000/year for companies of every size): https://endpts.com/subscribe
Already a paid subscriber? Sign in to Endpoints News to remove this message.

Linus Yip, Chief Strategist at First Shanghai Securities, told Reuters that a more realistic valuation helped set the stage for the latest IPO to succeed.

Histogenics shares eviscerated after FDA frowns on PhIII data

Histogenics $HSGX saw its share price get shredded after reporting their decision to drop NeoCart after the FDA demanded to see more data on NeoCart before they would accept a BLA for review. The stock dropped 75% as the biotech added that it is bringing in consultants to review strategic options — which includes bankruptcy protection. Histogenics shares are now deep in penny stock territory.

AbbVie pays India biotech $30M to partner on MALT1 for cancer

AbbVie has turned to India’s Lupin for an add-on approach for its oncology R&D group.

Lupin says that the pharma giant is paying $30 million in cash upfront to partner on its MALT1 inhibitors. The protein is linked with T-cell and B-cell lymphocyte activation, and AbbVie plans to test it for hematological cancers.

If it works, there are $947 million in milestones to collect.

Microbiome startup Vedanta scores $27M in Series C

Unlike rivals such as Seres and Rebiotix who are developing pills in an effort to treat disease by harnessing gut microbes found in healthy feces, Vedanta is developing a consortium of bacteria manufactured from pure, clonal cell banks that the biotech hopes can induce a range of immune responses.

The Cambridge, Massachusetts-based company, which has already joined forces with J&J’s $JNJ Janssen and Bristol-Myers Squibb $BMY, on Monday said it had raised $27 million in a Series C round from investors including the Bill & Melinda Gates Foundation, Bristol-Myers, Rock Springs Capital, Invesco Asset Management, Seventure Partners, and PureTech Health.

The money will be used to finance the development of 4 of the company’s experimental drugs, including a Phase I/II study of VE416 in food allergy, a Phase Ib/II study of VE800 and Bristol-Myer’s Opdivo in advanced or metastatic cancers, and the recently initiated Phase II study of VE303 in recurrent C. diff, which were created out of Vedanta’s cluster of bacterial strains.

arrow up arrow down arrow left arrow right icon close icon text icon help